Bioterrorism-related inhalational anthrax: Can extrapolated adult guidelines be applied to a pediatric population?

被引:2
|
作者
Place, Rick C.
Hanfling, Dan
Howell, John M.
Mayer, Thom A.
机构
[1] Inova Fairfax Hosp, Dept Emergency Med, Falls Church, VA 22042 USA
[2] George Washington Univ, Dept Emergency Med, Washington, DC USA
[3] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA
关键词
D O I
10.1089/bsp.2006.0011
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective. Since the 2001 anthrax attacks, an extensive body of literature has evolved, but there has been a limited focus on the management of pediatric-specific issues. We looked at the symptom complexes of all pediatric patients presenting to the emergency department of our hospital during this period and examined whether their presentations would likely allow current guidelines to be used as potential screening criteria to identify children infected with anthrax. Methods. We retrospectively reviewed emergency department records of all adult and pediatric patients (up to the age of 21 years) at Inova Fairfax Hospital during this time, when a large, and at the time ill-defined, group in the Washington, DC, metropolitan area was at risk for pulmonary anthrax. Two cases of anthrax infection were identified at this hospital in exposed adult postal workers. Screening algorithms (described by Mayer et al. and Hupert et al.) were applied to adult and pediatric patients with the presence of fever (38 degrees C), tachycardia, or other symptoms compatible with pulmonary anthrax. Specifically, the usefulness of these guidelines as potential screening tools to identify possibly infected children was examined. Results. Of 767 pediatric patients seen in the emergency department during the study period, 312 met criteria for review (41%; 95% CI : 37-44%). Four adult patients (0.4%; 95% CI : 0.1-0.9%) had at least five clinical symptoms, fever, and tachycardia; two of them had inhalational anthrax. No pediatric patient presented with five or more clinical symptoms. Twelve children (3.9%; 95% CI : 2-6.6%) presented with four clinical symptoms; five of the 12 had neither fever nor tachycardia. Children, particularly infants and toddlers, presented with nonspecific symptom complexes primarily limited to fever, vomiting, cough, and trouble breathing. Conclusions: Existing guidelines are likely to be unreliable as a screening tool for inhalational anthrax in children, largely because of the children's inability to adequately communicate a suggestive symptom complex.
引用
收藏
页码:35 / 42
页数:8
相关论文
共 50 条
  • [1] Clinical predictors of bioterrorism-related inhalational anthrax
    Gair, R
    LANCET, 2005, 365 (9455): : 214 - 215
  • [2] Pathology and pathogenesis of bioterrorism-related inhalational anthrax
    Guarner, J
    Jernigan, JA
    Shieh, WJ
    Tatti, K
    Flannagan, LM
    Stephens, DS
    Popovic, T
    Ashford, DA
    Perkins, BA
    Zaki, SR
    AMERICAN JOURNAL OF PATHOLOGY, 2003, 163 (02): : 701 - 709
  • [3] Clinical predictors of bioterrorism-related inhalational anthrax
    Kyriacou, DN
    Stein, AC
    Yarnold, PR
    Courtney, DM
    Nelson, RR
    Noskin, GA
    Handler, JA
    Frerichs, RR
    LANCET, 2004, 364 (9432): : 449 - 452
  • [4] Clinical predictors of bioterrorism-related inhalational anthrax - Response
    Kyriacou, DN
    LANCET, 2005, 365 (9455): : 215 - 215
  • [5] Bioterrorism-related inhalational anthrax in an elderly woman, Connecticut, 2001
    Griffith, KS
    Mead, P
    Armstrong, GL
    Painter, J
    Kelley, KA
    Hoffmaster, AR
    Mayo, D
    Barden, D
    Ridzon, R
    Parashar, U
    Teshale, EH
    Williams, J
    Noviello, S
    Perz, JF
    Mast, EE
    Swerdlow, DL
    Hadler, JL
    EMERGING INFECTIOUS DISEASES, 2003, 9 (06) : 681 - 688
  • [6] Death due to bioterrorism-related inhalational anthrax - Report of 2 patients
    Borio, L
    Frank, D
    Mani, V
    Chiriboga, C
    Pollanen, M
    Ripple, M
    Ali, S
    DiAngelo, C
    Lee, J
    Arden, J
    Titus, J
    Fowler, D
    O'Toole, T
    Masur, H
    Bartlett, J
    Inglesby, T
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (20): : 2554 - 2559
  • [7] Isolated case of bioterrorism-related inhalational anthrax, New York City, 2001
    Holtz, TH
    Ackelsberg, J
    Kool, JL
    Rosselli, R
    Marfin, A
    Matte, T
    Beatrice, ST
    Heller, MB
    Hewett, D
    Moskin, LC
    Bunning, ML
    Layton, M
    EMERGING INFECTIOUS DISEASES, 2003, 9 (06) : 689 - 696
  • [8] Bioterrorism-related inhalational anthrax: The first 10 cases reported in the United States
    Jernigan, JA
    Stephens, DS
    Ashford, DA
    Omenaca, C
    Topiel, MS
    Galbraith, M
    Tapper, M
    Fisk, TL
    Zaki, S
    Popovic, T
    Meyer, RF
    Quinn, CP
    Harper, SA
    Fridkin, SK
    Sejvar, JJ
    Shepard, CW
    McConnell, M
    Guarner, J
    Shieh, WJ
    Malecki, JM
    Gerberding, JL
    Hughes, JM
    Perkins, BA
    EMERGING INFECTIOUS DISEASES, 2001, 7 (06) : 933 - 944
  • [9] First case of bioterrorism-related inhalational anthrax, Florida, 2001: North Carolina investigation
    Maillard, JM
    Fischer, M
    McKee, KT
    Turner, LF
    Cline, JS
    EMERGING INFECTIOUS DISEASES, 2002, 8 (10) : 1035 - 1038
  • [10] Pathologic diagnosis of bioterrorism-related cutaneous anthrax
    Shieh, WJ
    Guarner, J
    Paddock, C
    Smith, C
    Tatti, K
    Morken, T
    Greer, P
    Ferebee-Harris, T
    Bartlett, J
    Montague, J
    Zaki, SR
    LABORATORY INVESTIGATION, 2003, 83 (01) : 264A - 264A